Ozurdex for Macular Edema Post Membrane Peeling
Epiretinal Membrane, Cellophane Maculopathy, Macular Edema
About this trial
This is an interventional treatment trial for Epiretinal Membrane focused on measuring epiretinal membrane, macular pucker, cellophane maculopathy, macular edema, retinal edema, ozurdex, dexamethasone, intravitreal implant
Eligibility Criteria
Inclusion Criteria
- Patients with macular edema who have had previous epi-retinal membrane peeling surgery for macular edema associated with epi-retinal membranes.
- All patients must have clear ocular media/lenses determined visually by the investigator in order to permit good quality stereoscopic fundus photography, fluorescein angiography and ocular coherence tomography.
Exclusion Criteria:
- Best corrected visual acuity 20/50 or better in the study eye
- Sub-macular hemorrhage in the study eye
- Sub-retinal fibrosis in the study eye
- Macular hole in the study eye
- Active inflammatory disease of the study eye
- Choroidal neovascularization in the study eye
- History of other ophthalmic disorders with the exception of cataract or previous cataract extraction in the study eye
- Active ocular infection in the study eye
- Previous subfoveal laser treatment in the study eye
- Previous verteporfin photodynamic therapy in the study eye
- Any systemic medical condition that would preclude them from undergoing surgery with monitored sedation.
Sites / Locations
- Retina Specialists PC
Arms of the Study
Arm 1
Arm 2
Arm 3
No Intervention
Experimental
Experimental
No Ozurdex
Ozurdex 3 months after surgery
Ozurdex 6 months or longer after surgery
Arm 1(control) - Patients who have had epi-retinal membrane peeling and have macular edema at least 3 months (90 days) after surgery. These patients will followed without Ozurdex. The patients will be treated with current standard of care, including topical and intravitreal or subtenon's medication.
Patients who have had epi-retinal membrane peeling and have residual macular edema 3 months after surgery. These patients will receive an Ozurdex implant
Patients who have had epiretinal membrane peeling and have residual macular edema at least 6 months after surgery